To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
NOW AVAILABLE!
IgG-Targeted Treatment for CIDP: Real-World Evidence on Transitioning from IVIg to Guide Clinical Practice
Congress Materials
Find clinical research and data presentations by argenx from recent or past Medical Congresses and Symposia.
argenx Pipeline
Our pipeline starts with strong science; aimed at translating immunology breakthroughs into differentiated medicines.
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.